EMPA-KIDNEY results: Empagliflozin reduces kidney disease progression and cardiovascular deaths
ฝัง
- เผยแพร่เมื่อ 18 ก.ย. 2024
- The EMPA-KIDNEY trial has demonstrated that empagliflozin reduces the risk of kidney disease progression or death from cardiovascular disease by 28% in people with chronic kidney disease.
Oxford Population Health are a world-leading research institute that investigates the causes and prevention of diseases.
Read more: bit.ly/3U7L4j8
Uhmazing! 😍